A schematic image shows how to detect brain specific mutations using next-generation sequencing technology with blood-brain paired samples. Simple comparison of non-overlapping mutations between affected and unaffected tissues is able to detect brain specific mutations. Credit: KAIST
Epilepsy is a brain disorder that afflicts more than 50 million people worldwide. Many epilepsy patients can control their symptoms through medication, but about 30% suffer from intractable epilepsy and are unable to manage the disease with drugs. Intractable epilepsy causes multiple seizures, permanent mental, physical, and developmental disabilities, and even death. Therefore, surgical removal of the affected area from the brain has been used as a treatment for patients with medically refractory seizures, but this too fails to provide a complete solution because only 60% of the patients who undergo surgery are rendered free of seizures.
A Korean research team led by Professor Jeong Ho Lee of the Graduate School of Medical Science and Engineering at the Korea Advanced Institute of Science and Technology (KAIST) and Professor Dong-Seok Kim of the Epilepsy Research Center at Yonsei University College of Medicine has recently identified brain somatic mutations in the gene of mechanistic target of rapamycin (MTOR) as the cause of focal cortical dysplasia type II (FCDII), one of the most important and common inducers to intractable epilepsy, particularly in children. They propose a targeted therapy to lessen epileptic seizures by suppressing the activation of mTOR kinase, a signaling protein in the brain. Their research results were published online in Nature Medicine on March 23, 2015.
FCDII contributes to abnormal developments of the cerebral cortex, ranging from cortical disruption to severe forms of cortical dyslamination, balloon cells, and dysplastic neurons. The research team studied 77 FCDII patients with intractable epilepsy who had received surgery to remove the affected regions from the brain. The researchers used various deep sequencing technologies to conduct comparative DNA analysis of the samples obtained from the patients' saliva or brain and blood. They reported that about 16% of the studied patients had somatic mutations in their brain. Such mutations, however, did not take place in their blood or saliva DNA.
Professor Jeong Ho Lee of KAIST said, "This is an important finding. Unlike our previous belief that genetic mutations causing intractable epilepsy exist anywhere in the human body including the blood, specific gene mutations incurred only in the brain can lead to intractable epilepsy. From our animal model, we could see how a small fraction of mutations carrying neurons in the brain could affect its entire function."
A schematic image shows how to generate a focal cortical dysplasia mouse model. This mouse model opens a new window of drug screening for seizure patients. Credit: KAIST
The research team recapitulated the pathogenesis of intractable epilepsy by inducing the focal cortical expression of mutated mTOR in the mouse brain via an electroporation method and observed as the mouse developed epileptic symptoms. They then treated these mice with a drug called "rapamycin" to inhibit the activity of mTOR protein and observed that it suppressed the development of epileptic seizures with cytomegalic neurons.
Targeted medicine can rescue focal cortical dysplasia symptoms including cytomegalic neuron & intractable epilepsy. Credit: KAIST
"Our study offers the first evidence that brain-somatic-activating mutations in MTOR cause FCDII, and we identified mTOR as a treatment target for intractable epilepsy," said co-author Dr. Dong-Seok Kim, a neurosurgeon at Yonsei Medical Center with the most surgical experiences in treating patients with this condition.
Explore further: Researchers identify gene linked with early epilepsy
More information: "Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy." DOI: 10.1038/nm.3824
Medical Xpress on facebook
Related Stories
Researchers identify gene linked with early epilepsy
Certain types of early-onset epilepsy are caused by previously unknown mutations of a potassium channel gene, KCNA2. The mutations disrupt the electrical balance in the brain in two ways. In some patients, the flow of potassium ...
GW leads clinical trial to reduce epileptic seizures in people with temporal lobe epilepsy
A first-of-its-kind clinical trial at the George Washington University (GW) Medical Faculty Associates employs low-frequency deep brain stimulation to potentially help reduce epileptic seizures in patients with mesial temporal ...
Fatal uncoupling in the epileptic brain
Epilepsy is a very prevalent neurological disorder. Approximately one-third of patients are resistant to currently available therapies. A team of researchers under the guidance of the Institute of Cellular ...
Study finds novel compound switches off epilepsy development
Researchers at the LSU Health New Orleans Neuroscience Center of Excellence have found that a novel compound they discovered helps curtail the onset and progression of temporal lobe epilepsy. The finding, which may contribute ...
Adenosine therapy reduces seizures and progression of epilepsy
Epilepsy is characterized by recurrent seizures that present in many different ways. In some cases epileptic patients exhibit a progressive increase in both frequency and severity of seizures. Epigenetic changes such as DNA ...
Recommended for you
Potential for ALS treatment found in three proteins
Where ALS comes from and how it progresses are mysteries that continue to vex medical science. But recent research at Sweden's KTH Royal Institute of Technology has found three proteins that could shed some ...
Cerebellar ataxia can't be cured, but some cases can be treated
No cures are possible for most patients who suffer debilitating movement disorders called cerebellar ataxias.
Deuterated sigma-1 agonist showed anti-seizure activity in traumatic brain injury models
Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma- ...
Genomewide screen of learning in zebrafish identifies enzyme important in neural circuit
Researchers at the Perelman School of Medicine at the University of Pennsylvania describe the first set of genes important in learning in a zebrafish model in the journal Neuron this week. "Using an in-dep ...
Research into brain's ability to heal itself offers hope for novel treatment of brain injury
Innovative angles of attack in research that focus on how the human brain protects and repairs itself will help develop treatments for one of the most common, costly, deadly and scientifically frustrating medical conditions ...
Understanding and healing concussion
In recent years, many Canadians have become aware of traumatic brain injury (TBI) through the reporting of concussions suffered by hockey players and other athletes. In addition to widespread sports-related ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
A schematic image shows how to detect brain specific mutations using next-generation sequencing technology with blood-brain paired samples. Simple comparison of non-overlapping mutations between affected and unaffected tissues is able to detect brain specific mutations. Credit: KAIST
Epilepsy is a brain disorder that afflicts more than 50 million people worldwide. Many epilepsy patients can control their symptoms through medication, but about 30% suffer from intractable epilepsy and are unable to manage the disease with drugs. Intractable epilepsy causes multiple seizures, permanent mental, physical, and developmental disabilities, and even death. Therefore, surgical removal of the affected area from the brain has been used as a treatment for patients with medically refractory seizures, but this too fails to provide a complete solution because only 60% of the patients who undergo surgery are rendered free of seizures.
A Korean research team led by Professor Jeong Ho Lee of the Graduate School of Medical Science and Engineering at the Korea Advanced Institute of Science and Technology (KAIST) and Professor Dong-Seok Kim of the Epilepsy Research Center at Yonsei University College of Medicine has recently identified brain somatic mutations in the gene of mechanistic target of rapamycin (MTOR) as the cause of focal cortical dysplasia type II (FCDII), one of the most important and common inducers to intractable epilepsy, particularly in children. They propose a targeted therapy to lessen epileptic seizures by suppressing the activation of mTOR kinase, a signaling protein in the brain. Their research results were published online in Nature Medicine on March 23, 2015.
FCDII contributes to abnormal developments of the cerebral cortex, ranging from cortical disruption to severe forms of cortical dyslamination, balloon cells, and dysplastic neurons. The research team studied 77 FCDII patients with intractable epilepsy who had received surgery to remove the affected regions from the brain. The researchers used various deep sequencing technologies to conduct comparative DNA analysis of the samples obtained from the patients' saliva or brain and blood. They reported that about 16% of the studied patients had somatic mutations in their brain. Such mutations, however, did not take place in their blood or saliva DNA.
Professor Jeong Ho Lee of KAIST said, "This is an important finding. Unlike our previous belief that genetic mutations causing intractable epilepsy exist anywhere in the human body including the blood, specific gene mutations incurred only in the brain can lead to intractable epilepsy. From our animal model, we could see how a small fraction of mutations carrying neurons in the brain could affect its entire function."
A schematic image shows how to generate a focal cortical dysplasia mouse model. This mouse model opens a new window of drug screening for seizure patients. Credit: KAIST
The research team recapitulated the pathogenesis of intractable epilepsy by inducing the focal cortical expression of mutated mTOR in the mouse brain via an electroporation method and observed as the mouse developed epileptic symptoms. They then treated these mice with a drug called "rapamycin" to inhibit the activity of mTOR protein and observed that it suppressed the development of epileptic seizures with cytomegalic neurons.
Targeted medicine can rescue focal cortical dysplasia symptoms including cytomegalic neuron & intractable epilepsy. Credit: KAIST
"Our study offers the first evidence that brain-somatic-activating mutations in MTOR cause FCDII, and we identified mTOR as a treatment target for intractable epilepsy," said co-author Dr. Dong-Seok Kim, a neurosurgeon at Yonsei Medical Center with the most surgical experiences in treating patients with this condition.
Explore further: Researchers identify gene linked with early epilepsy
More information: "Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy." DOI: 10.1038/nm.3824
Medical Xpress on facebook
Related Stories
Researchers identify gene linked with early epilepsy
Certain types of early-onset epilepsy are caused by previously unknown mutations of a potassium channel gene, KCNA2. The mutations disrupt the electrical balance in the brain in two ways. In some patients, the flow of potassium ...
GW leads clinical trial to reduce epileptic seizures in people with temporal lobe epilepsy
A first-of-its-kind clinical trial at the George Washington University (GW) Medical Faculty Associates employs low-frequency deep brain stimulation to potentially help reduce epileptic seizures in patients with mesial temporal ...
Fatal uncoupling in the epileptic brain
Epilepsy is a very prevalent neurological disorder. Approximately one-third of patients are resistant to currently available therapies. A team of researchers under the guidance of the Institute of Cellular ...
Study finds novel compound switches off epilepsy development
Researchers at the LSU Health New Orleans Neuroscience Center of Excellence have found that a novel compound they discovered helps curtail the onset and progression of temporal lobe epilepsy. The finding, which may contribute ...
Adenosine therapy reduces seizures and progression of epilepsy
Epilepsy is characterized by recurrent seizures that present in many different ways. In some cases epileptic patients exhibit a progressive increase in both frequency and severity of seizures. Epigenetic changes such as DNA ...
Recommended for you
Potential for ALS treatment found in three proteins
Where ALS comes from and how it progresses are mysteries that continue to vex medical science. But recent research at Sweden's KTH Royal Institute of Technology has found three proteins that could shed some ...
Cerebellar ataxia can't be cured, but some cases can be treated
No cures are possible for most patients who suffer debilitating movement disorders called cerebellar ataxias.
Deuterated sigma-1 agonist showed anti-seizure activity in traumatic brain injury models
Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma- ...
Genomewide screen of learning in zebrafish identifies enzyme important in neural circuit
Researchers at the Perelman School of Medicine at the University of Pennsylvania describe the first set of genes important in learning in a zebrafish model in the journal Neuron this week. "Using an in-dep ...
Research into brain's ability to heal itself offers hope for novel treatment of brain injury
Innovative angles of attack in research that focus on how the human brain protects and repairs itself will help develop treatments for one of the most common, costly, deadly and scientifically frustrating medical conditions ...
Understanding and healing concussion
In recent years, many Canadians have become aware of traumatic brain injury (TBI) through the reporting of concussions suffered by hockey players and other athletes. In addition to widespread sports-related ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment